Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.59 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL115674 | 0.98 | NCF1 (0.72) | NCF1LMNAKMT2AMAPTHSP90AA1 | |
| SCHEMBL29961464 | 0.98 | NCF1 (0.72) | NCF1LMNAKMT2AMAPTHSP90AA1 | |
| Hydrochloric Acid SCHEMBL29862816 | 0.96 | NCF1 (0.69) | NCF1LMNAKMT2AMAPTHSP90AA1 | |
| Hydrochloric Acid SCHEMBL6119015 | 0.96 | NCF1 (0.69) | NCF1LMNAKMT2AMAPTHSP90AA1 | |
| Aniline SCHEMBL2858457 | 0.88 | NCF1 (0.66) | NCF1LMNAKMT2AMAPTHSP90AA1 | |
| Pyrimidine SCHEMBL28845436 | 0.88 | NCF1 (0.60) | NCF1LMNAKMT2AMAPTHSP90AA1 | |
| Quinolin-4-Amine SCHEMBL20986747 | 0.84 | NCF1 (0.95) | NCF1LMNAKMT2AMAPTHSP90AA1 | |
| Hydrazinecarboxamide SCHEMBL1464164 | 0.82 | NCF1 (0.53) | NCF1LMNAKMT2AMAPTHSP90AA1 | |
| Quinolin-4-Amine SCHEMBL278276 | 0.82 | NCF1 (1.00) | NCF1LMNAKMT2AMAPTHSP90AA1 | |
| Quinolin-4-Amine SCHEMBL29493365 | 0.82 | NCF1 (1.00) | NCF1LMNAKMT2AMAPTHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109400594-A | Metal enzyme inhibitor compound | 威尔金制药(NC)有限公司 | 2019-03-01 | — | — | CN | disclosed |
| EP-2723731-B1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-8940735-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8883797-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| CN-103930418-A | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS INC | 2014-07-16 | — | — | CN | disclosed |
| CN-103857675-A | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS INC | 2014-06-11 | — | — | CN | disclosed |
| EP-2723730-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-2723731-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2014-04-30 | — | — | EP | disclosed |
| US-20130012503-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| WO-2012177725-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177728-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20120329802-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012503-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | NCF1 939/4885LMNA 4266/4885KMT2A 1886/4885 |
| US-20120329802-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | NCF1 939/4885LMNA 4266/4885KMT2A 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.